The 2026 compounded GLP-1 guide

A clear guide to the compounded GLP-1 class in 2026 — semaglutide, tirzepatide, retatrutide. Differences, presentations, FDA landscape, and supplier…

The compounded GLP-1 class in 2026 centers on semaglutide, tirzepatide, and retatrutide. None are FDA-approved as compounded products. Responsible U.S. suppliers ship with third-party COAs, signed buyer agreements, and clear research / investigational / licensed-professional-use labeling.

GLP-1 receptor agonists are the most-searched metabolic peptide category in the United States. Three molecules dominate the compounded GLP-1 lane in 2026: semaglutide (GLP-1), tirzepatide (dual GIP/GLP-1), and retatrutide (triple GIP/GLP-1/glucagon, still in late-stage clinical trials at the branded level). This guide covers the differences that matter for buyers.

The three molecules at a glance

• Semaglutide — GLP-1 only. Most-studied, longest-available, mainstream compounded presentations.
• Tirzepatide — dual GIP/GLP-1. Mechanistically broader; supply tightened later than semaglutide.
• Retatrutide — triple GIP/GLP-1/glucagon. Investigational at the branded level; compounded supply is limited and the most variable in price.

Why 'compounded' is its own lane

All three molecules exist in branded, FDA-approved or late-stage clinical-trial forms. The compounded lane is regulatory and operationally distinct: a licensed U.S. compounding partner prepares the molecule to a specified concentration, with batch records, for research, investigational, or licensed-professional use only.

Compounded preparations are not bioequivalent to the branded products from a regulatory standpoint and are not interchangeable with them. They exist primarily to provide access to the molecule at concentrations or in combinations the branded products don't offer.

What changed in 2024–2026

• FDA removed semaglutide from the shortage list in early 2025; tirzepatide came off later in 2024.
• Compounders moved to research / investigational / licensed-professional-use frameworks.
• Bulk telehealth GLP-1 operations consolidated, exited, or restructured under stricter protocols.
• Documentation requirements rose: COAs per batch, signed buyer agreements, clearer labeling.

Choosing a compounded GLP-1 supplier

• Third-party COA for the exact batch shipped — not a stock PDF.
• Named U.S. compounding partner with verifiable address.
• Clear research / investigational / licensed-professional-use labeling.
• Signed Peptide Agreement before first order.
• Cold-chain shipping policy with stated post-reconstitution stability window.
• Real human support during posted business hours.

Related peptides

• Semaglutide — A long-acting GLP-1 receptor agonist extensively studied for metabolic health.
• Tirzepatide — Dual GIP and GLP-1 receptor agonist studied for metabolic and weight outcomes.
• Retatrutide — Triple-receptor (GLP-1 / GIP / glucagon) agonist in late-stage clinical trials.

Sources

• FDA: Compounded GLP-1 medications — what patients and providers should know — U.S. Food & Drug Administration (accessed 2026-06-27): https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
• Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — New England Journal of Medicine (accessed 2026-06-27): https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
• Retatrutide phase 2 trial in obesity (TRIUMPH-1) — New England Journal of Medicine (accessed 2026-06-27): https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
• USP <797> Pharmaceutical Compounding — Sterile Preparations — United States Pharmacopeia (accessed 2026-06-27): https://www.usp.org/compounding/general-chapter-797

Important

All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.

Frequently asked questions

What is a compounded GLP-1?

A compounded GLP-1 is a non-FDA-approved preparation of a GLP-1 class molecule (semaglutide, tirzepatide, retatrutide) made by a licensed U.S. compounding partner for research, investigational, or licensed-professional use only.

Are compounded GLP-1s legal in 2026?

They can be legally prepared by licensed U.S. compounding partners under current FDA and state pharmacy frameworks. The compliance lane has narrowed since 2024.

Which compounded GLP-1 should I choose?

That is a decision for you and a licensed practitioner, not a supplier. Semaglutide is the most-studied; tirzepatide adds dual GIP/GLP-1 activity; retatrutide is the newest and most variable in supply.

Does Clarity Wellness carry all three?

Yes — semaglutide, tirzepatide, and retatrutide are all in our member catalog when supply allows. Pricing and current concentrations are visible to members after sign-in with a VIP code.

How are compounded GLP-1s shipped?

From our North Carolina hub to all 50 U.S. states, $25 flat-rate, 5–10 business days, fully tracked, with cold-chain protocols where required.